View abstract

This abstract is assigned to session FAB: Fluorescein Angiography Club Belgium

Title

Contribution of intravitreal bevacizumab in macular edema due to central retinal vein occlusion (CRVO).

Purpose	To evaluate the effects of intravitreal bevacizumab on visual acuity and central macular thickness in eyes with macular edema due to central retinal vein occlusions (CRVO).
Methods	This retrospective study was conducted on patients having macular edema due to CRVO and treated with IVT bevacizumab between January 2006 and March 2011, in our hospital. All patients underwent visual acuity measurement, optical coherence tomography imaging, and ophthalmoscopic examination at baseline and follow-up visits.
Results	31 eyes of 31 patients were included in the study (mean age 68 years, follow-up between 5 and 24 months). Initial mean visual acuity was 0.8 LogMAR. At 5, 12, and 18 months of follow-up, mean visual acuity improved respectively to 0.58 LogMAR (n = 31, p = 0.0125), 0.44 LogMAR (n = 18, p = 0.0092), and 0.64 LogMAR (n = 12, p = 0.6407). The mean central macular thickness at baseline was 664 μm. At 5, 12, 18 and 24 months of follow-up, mean central macular thickness had decreased respectively to 423 μm (n = 31, p = 0.0000), 424 μm (n = 18, p = 0.0008), 438 μm (n = 12, p = 0.050) and 420 μm (n = 7, p = 0.0216). No complications were recorded.
Conclusion	These encouraging results confirm the data of previous studies identifying IVT bevacizumab as a promising therapeutic option for macular edema due to OVCR.

Author 1

Last name	ASSOULINE
Initials	JA
Department	ULB
City	Bruxelles

Author 2

Last name	CORDONNIER
Initials	MC
Department	Erasme
City	Bruxelles

Author 3

Last name	RASQUIN
Initials	F
Department	Erasme
City	Bruxelles